Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 84386-153

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 84386-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Alfuzosin Fig1)

Figure-1 (Alfuzosin Fig1)
A line graph showing alfuzosin plasma concentration (ng/mL) over time (hours) comparing fed and fasted states. The x-axis represents time from 0 to 24 hours, and the y-axis shows plasma concentration from 0 to 14 ng/mL. Data points indicate higher plasma levels in the fed state versus fasted, with error bars for variability.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
A line graph depicting mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing Alfuzosin Hydrochloride and placebo groups. The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis shows mean change values. The Alfuzosin Hydrochloride group shows a greater decrease over time compared to placebo.*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
A line graph titled 'Mean Change from Baseline in IPSS Total Symptom Score: Trial 2' comparing placebo and alfuzosin hydrochloride treatment groups over 84 days. The x-axis shows days of treatment (0, 28, 56, 84) and the y-axis shows mean change from baseline. Two lines represent placebo (triangles) and alfuzosin hydrochloride (squares), illustrating a greater symptom score reduction over time in the alfuzosin group compared to placebo.*
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
A line graph showing mean change from baseline in IPSS Total Symptom Score over 84 days of treatment, comparing Alfuzosin Hydrochloride and placebo groups. The y-axis represents the change in score, and the x-axis represents days of treatment, with Alfuzosin Hydrochloride showing a greater reduction in symptoms over time.*
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
A line graph displaying mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment comparing alfuzosin hydrochloride and placebo groups. Alfuzosin shows a marked increase over time, stabilizing around 1.7 mL/s, while placebo remains near 0.3 mL/s. Statistical significance is indicated (p < 0.001).*
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
A line graph depicting the mean change from baseline in peak urine flow rate (mL/s) over days of treatment up to 84 days. Two groups are shown: placebo and alfuzosin hydrochloride. The alfuzosin hydrochloride group shows a greater increase in peak urine flow rate compared to placebo throughout the treatment period.*
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
A line graph depicting the mean change from baseline in peak urine flow rate (mL/s) over days of treatment for two groups: placebo and Alfuzosin Hydrochloride. The x-axis shows days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change in mL/s. Two lines represent results for placebo and Alfuzosin Hydrochloride groups.*
FDA Label Image

Figure (Alfuzosin Fig8)

Figure (Alfuzosin Fig8)
Label for Alfuzosin Hydrochloride Extended-Release Tablets USP 10 mg by Aurobindo Pharma Limited. The label indicates 30 film-coated extended-release tablets, with directions to swallow whole and not to chew or crush. Storage instructions specify 20° to 25°C with protection from light and moisture. Distributed by Aurobindo Pharma USA, Inc., with a barcode and a note on printing GTIN, serial number, expiry date, and lot during packing.*
FDA Label Image

Structure (Alfuzosin Str)

Structure (Alfuzosin Str)
Chemical structure of Alfuzosin Hydrochloride showing its molecular components including aromatic rings, amino groups, and a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.